Therapure to manufacture VBI coronavirus vaccines

By The Science Advisory Board staff writers

August 18, 2020 -- Therapure Biomanufacturing has signed an agreement with VBI Vaccines for the manufacture of its coronavirus vaccine candidates.

Under the agreement, Therapure will be responsible for the manufacturing of the vaccine drug substance as well as the aseptic fill of the drug product at its facility in Mississauga, Ontario. The company will provide current good manufacturing practice biomanufacturing capabilities to advance the vaccine candidates through clinical studies.

VBI is using its enveloped virus-like particle (eVLP) platform for the development of a preventative pancoronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS), in collaboration with the National Research Council of Canada.

COVID-19 vaccine candidates show progress amid challenges
As the COVID-19 outbreak advances worldwide, companies are stepping up to the challenge to develop a potential vaccine. There are over 75 confirmed COVID-19...

Copyright © 2020 scienceboard.net


Conferences
CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
6th Annual CAR-TCR Summit
August 30 - September 2
Online
European Congress of Immunology (ECI) 2021
September 1-4
Belgrade Serbia
Medical Affairs Strategic Summit (MASS)
September 13-15
New Brunswick, New Jersey United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter